Deborah Keye, PA
Medical · Salt Lake City, UTNPI 1164559159
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AbbVie at 39.6% of the total. Reporting peaked in 2023 at $1,042 and has fallen 81.8% since, to $190 in 2025.
Across 159 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$222
- Bayer$204
- Idorsia Pharmaceuticals US Inc$181
- Johnson & Johnson$168
- Boehringer Ingelheim$164
- plus $891 from 24 others
What the payments were for
- Food & beverage$2,98198%
- Education$502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 63 | $1,201 |
| Lilly USA, LLC | 14 | $222 |
| Bayer | 10 | $204 |
| Idorsia Pharmaceuticals US Inc | 7 | $181 |
| Johnson & Johnson | 3 | $168 |
| Boehringer Ingelheim | 8 | $164 |
| Novo Nordisk | 6 | $108 |
| Pfizer | 6 | $88 |
| Lucid Diagnostics Inc. | 6 | $80 |
| Currax Pharmaceuticals LLC | 3 | $63 |
| Biohaven Pharmaceuticals, Inc. | 3 | $60 |
| Amarin Pharma, Inc. | 3 | $53 |
| AstraZeneca | 4 | $53 |
| Collegium Pharmaceutical, Inc. | 3 | $51 |
| GSK | 3 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Exact Sciences | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Abbott | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Cranial Technologies, Inc | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Collaborative Care Diagnostics, LLC | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Qorumpartners | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$118
How this compares
$3,031 in reported general payments places this provider in the 75th percentile of 263 medical providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 11 | $17,979 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 28 | $927 |
| Bupropion XlBupropion Hcl | 17 | $515 |
| Clonazepam | 13 | $509 |
| Levothyroxine Sodium | 39 | $494 |
| Atorvastatin Calcium | 59 | $493 |
| Trazodone Hcl | 26 | $487 |
| Estradiol | 15 | $466 |
| Omeprazole | 22 | $444 |
| Rosuvastatin Calcium | 33 | $438 |
| Duloxetine Hcl | 13 | $418 |
| Topiramate | 15 | $387 |
| Gabapentin | 13 | $333 |
| Olmesartan Medoxomil | 19 | $293 |
| Zolpidem Tartrate | 20 | $292 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $222 | $17,97911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 263 medical providers in Utah.
Other medical in Salt Lake City
- Elisa WilcoxSalt Lake City$178K
- Viet leSalt Lake City$42K
- Carmelo DiazSalt Lake City$35K
- Shari CombeSalt Lake City$22K
- Abbie SiebenhaarSalt Lake City$7K
- Gerald KeltySalt Lake City$6K
- Alanna JorgensenSalt Lake City$6K
- Alyssa SmithSalt Lake City$5K
- Michael SwinyerSalt Lake City$5K
- Louise TobeySalt Lake City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.